REVERSIBLE TRABECULAR BONE DENSITY LOSS FOLLOWING INDUCED HYPO‐OESTROGENISM WITH THE GnRH ANALOGUE BUSERELIN IN PREMENOPAUSAL WOMEN
Buserelin treatment for endometriosis in premenopausal women caused a reversible loss in lumbar vertebral trabecular bone density but only a non-significant trend toward reduced femoral cortical bone mineral content.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (21)
- Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis--comparison of two dose regimens. via openalex
- Use of a super active luteinizing hormone releasing hormone (LHRH) agonist in the treatment of menorrhagia via openalex
- W1997894565 via openalex
- W2004236425 via openalex
- W2011846252 via openalex
- W2014486464 via openalex
- W2027109535 via openalex
- W2029087187 via openalex
- W2050557100 via openalex
- W2061801939 via openalex
- W2077150151 via openalex
- W2116092458 via openalex
- W2320428286 via openalex
- W2331313671 via openalex
- W2336790305 via openalex
- W2462972130 via openalex
- W4245583620 via openalex
- W4246359025 via openalex
- W1968453570 via openalex
- W4294307685 via openalex
- W1970836431 via openalex
Cited by (38)
- Use of gonadotropin-releasing hormone agonists for ovarian preservation in patients receiving cyclophosphamide for systemic lupus erythematosus: A meta-analysis 2022
- Gonadotropin releasing hormone agonists: Expanding vistas 2011
- Medical Management of Endometriosis 2006
- Use of a gonadotropin‐releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus 2005
- Long-term effects on bone mineral density and bone metabolism of 6 months’ treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate 2005
- Emerging drugs for endometriosis 2004
- Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone 2002
- Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up 2000
- Managing endometriosis 1999
- Today's treatments: medical, surgical and in partnership 1999
- Effects of Add-Back Therapy on Bone Mineral Density and Pyridinium Crosslinks in Patients with Endometriosis Treated with Gonadotropin-Releasing Hormone Agonists 1999
- Hormone replacement therapy following hysterectomy for endometriosis 1998
- MODERN MEDICAL MANAGEMENT OF ENDOMETRIOSIS 1997
- Intermittent etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist 1997
- Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists 1997
- Modern Approach to Endometriosis 1997
- Reduction of bone mineral density by gonadotropin‐releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration 1996
- Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin 1995
- Bone mineral loss during lactation and recovery after weaning 1995
- Evidence that the loss of bone mass induced by GnRH agonists is not totally recovered 1995
- The impact of bone loss in women with endometriosis 1995
- Effect of gonadotropin-releasing hormone agonist on the bone mineral density of patients with endometriosis 1994
- Impact of different GnRH analogs in benign gynecological disorders related to their chemical structure, delivery systems and dose 1994
- A Risk Benefit Assessment of Drugs Used in the Treatment of Endometriosis 1994
- Nafarelin therapy in endometriosis: Long-term effects on bone mineral density 1994
- Medical management of endometriosis 1993
- Endometriosis: still an enigma 1993
- GnRH Agonists in the Treatment of Endometriosis 1993
- Hormone Treatment Related Bone Mineral Content Changes in Japanese Women with Endometriosis 1993
- Gonadotropin-releasing hormone agonist plus estrogen-progestin “add-back” therapy for endometriosis-related pelvic pain 1993
- Endometriosetherapie mit Enantone®-Gyn Monats-Depot 1992
- The Induction of Amenorrhoea 1992
- A randomized double blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone 1992
- Treatment of endometriosis 1992
- GnRH analogues in the treatment of endometriosis — rationale and efficacy 1991
- The use of danazol as a treatment of endometriosis 1991
- Buserelin 1990
- Long-term suppression of ovarian function by a luteinizing-hormone releasing hormone agonist implant in patients with endometriosis 1990
Source provenance
- europepmc
- last seen: 2026-10-01T06:15:55.914501+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:09:20.810540+00:00